June 9, 2020 / 1:14 PM / a month ago

BRIEF-OncoSec Expands Keynote-890 Trial Into First-Line Metastatic Triple Negative Breast Cancer With Tavo And Keytruda Plus Chemotherapy

June 9 (Reuters) - OncoSec Medical Inc:

* ONCOSEC EXPANDS KEYNOTE-890 TRIAL INTO FIRST-LINE METASTATIC TRIPLE NEGATIVE BREAST CANCER (MTNBC) WITH TAVO™ AND KEYTRUDA® PLUS CHEMOTHERAPY

* ONCOSEC MEDICAL - COHORT 2 WILL BE ADDED AS A SECOND ARM TO ONGOING KEYNOTE-890 STUDY

* ONCOSEC MEDICAL - SHOULD POSITIVE RESULTS FROM KEYNOTE 890 COHORT 2 BE OBSERVED, CO PLANS TO EXPAND IT & UTILIZE RESULTS TO SEEK ACCELERATED APPROVAL Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below